

February 5, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUOPHARMA	To The Corporate Relations Department BSE LIMITED Phiroze Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir/Madam,

Sub: Disposal of business assets of Eugia US Manufacturing LLC, a wholly owned step- down subsidiary of the Company – Reg.,

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, we hereby inform you that Eugia US Manufacturing LLC, USA, a wholly owned step-down subsidiary of the Company, has entered into an asset purchase agreement with Empower Clinic Services New Jersey, LLC to dispose of its business assets as a going concern with related assets and liabilities and employees.

Eugia US Manufacturing LLC is not a material subsidiary of the Company and accordingly, the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part B of Schedule III of the aforesaid regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023, is enclosed as “Annexure I”.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl.: Annexure I

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd.off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/ 2374 6833

Annexure I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
read with

SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sale of assets of Eugia US Manufacturing LLC, a Wholly Owned Step-down Subsidiary

Sr. No.	Particulars	Description																
1	Name of the subsidiary whose business assets are disposed of	Eugia US Manufacturing LLC, a wholly owned step-down subsidiary of the Company, is disposing of its business assets under asset purchase agreement as a going concern with related assets and liabilities and employees since capacities and operations are being ramped up in other units of the Company and it shall, upon closing, enter into contract manufacturing arrangements with the buyer.																
2	The amount and percentage of turnover or revenue or income and net worth of the listed entity contributed by such division, or subsidiary during the last financial year	For the period April 1, 2022 to March 31, 2023 (INR in Mio): <table border="1" data-bbox="762 1048 1444 1429"> <thead> <tr> <th>Particulars</th> <th>Eugia US Manufacturing LLC</th> <th>Aurobindo Pharma Limited (Consolidated)</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Revenue from operations</td> <td>-</td> <td>248,553.8</td> <td>-</td> </tr> <tr> <td>Profit after Tax</td> <td>(155.5)</td> <td>19,276.5</td> <td>-</td> </tr> <tr> <td>Net Worth</td> <td>(390.9)</td> <td>268,518.5</td> <td>-</td> </tr> </tbody> </table>	Particulars	Eugia US Manufacturing LLC	Aurobindo Pharma Limited (Consolidated)	%	Revenue from operations	-	248,553.8	-	Profit after Tax	(155.5)	19,276.5	-	Net Worth	(390.9)	268,518.5	-
Particulars	Eugia US Manufacturing LLC	Aurobindo Pharma Limited (Consolidated)	%															
Revenue from operations	-	248,553.8	-															
Profit after Tax	(155.5)	19,276.5	-															
Net Worth	(390.9)	268,518.5	-															
3	Date on which the agreement for sale has been entered into	February 3, 2024 (EST) which is February 4, 2024 (IST).																
4	The expected date of completion of Sale/disposal	The transaction is expected to close within 90 days from the date of definitive agreement subject to fulfilment of closing conditions referenced in the definitive agreement including financial closure by the buyer.																
5	Consideration received from such sale/disposal	Cash of USD 52 million to be received from the disposal, plus USD 58 Mn in lease payments made to Eugia US Manufacturing LLC and/or its affiliates, over the 20 years lease term including extensions.																

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/ 2374 6833

6	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group of the companies.	Empower Clinic Services New Jersey, LLC is the buyer. The buyer does not belong to the promoter/promoter group companies
7	Whether the transaction would fall with in related party transactions?	The transaction is not a related party transaction
8	Whether the sale, lease or disposal of the undertaking is outside the Scheme of Arrangement?	Not Applicable
9	Additionally, in case of slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/ 2374 6833